Treatment with neurohormonal inhibitors and prognostic outcome in pulmonary arterial hypertension with risk factors for left heart disease

Table 1 Baseline characteristics of the study population

Variable	NEUi non-users, n = 30	NEUi users, n = 27	P
Age in yr	60.1 ± 14.5	67.6 ± 11.9	0.039
Men/Women, n (%)	11 (36.7)/19 (63.3)	9 (33.3)/18 (66.7)	0.988
Follow-up in yr	4.0 ± 2.7	4.5 ± 3.3	0.504
Dead at follow-up, n (%)	17 (56.7)	7 (25.9)	0.038
BMI in kg/m2	23.5 ± 3.5	25.9 ± 4.4	0.025
Arterial hypertension, n (%)	12 (40.0)	20 (74.1)	0.020
Smoking habits, n (%)	6 (20.0)	14 (51.9)	0.025
Dyslipidemia, n (%)	7 (23.3)	12 (44.4)	0.160
Diabetes mellitus, n (%)	2 (6.7)	5 (18.5)	0.339
Supraventricular arrhythmias, n (%)	4 (13.3)	7 (25.9)	0.386
Coronary artery disease, n (%)	0 (0)	5 (18.5)	0.046
eGFR in mL/min/1.73 m2 [CKD-EPI]	73.7 ± 24.7	58.7 ± 22.7	0.022
WHO-FC	2.2 ± 0.76	2.3 ± 0.47	0.572
6MWD in m	383.9 ± 129.7	374.3 ± 145.1	0.845
NT-proBNP in ng/mL	714.9 ± 692.4	808.7 ± 617.9	0.593
Systolic PAP in mmHg	74.7 ± 26.3	71.0 ± 21.3	0.569
Diastolic PAP in mmHg	27.5 ± 11.6	26.3 ± 9.6	0.681
Mean PAP in mmHg	46.2 ± 16.1	43.6 ± 13.6	0.509
Right atrial pressure in mmHg	8.3 ± 3.9	10.5 ± 5.0	0.063
PAWP in mmHg	10.5 ± 2.9	11.7 ± 2.5	0.105
PVR in Wood unit	9.0 ± 5.4	8.6 ± 4.6	0.789
Cardiac index in L/min/m2	2.6 ± 0.9	2.4 ± 0.6	0.258

BMI: Body mass index; NEUi: Neurohormonal inhibitors; CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration; eGFR: Estimated glomerular filtration rate; NT-proBNP: N-terminal pro-brain natriuretic peptide; PAP: Pulmonary arterial pressure; PAWP: Pulmonary artery wedge pressure; PVR: Pulmonary vascular resistance; 6MWD: 6-min walking distance; WHO-FC: World Health Organization functional class.